Viking Therapeutics, Inc. (VKTX)
| Previous close | 64.23 |
| Open | 64.56 |
| Bid | 62.65 x 100 |
| Ask | 63.37 x 100 |
| Day's range | 62.67 - 64.63 |
| 52-week range | 8.28 - 99.41 |
| Volume | |
| Avg. volume | 6,325,330 |
| Market cap | 6.944B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Bloomberg
Weight-Loss Upstart Viking Needs a Deal to Vie With Lilly and Novo
(Bloomberg) -- Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking Therapeutics Inc. shares skyrocketing. But to reach the next level the biopharmaceutical developer likely needs a partner — or a buyer.Most Read from BloombergThese Flight Routes Suffer the World’s Worst TurbulenceOne Dead After Singapore Air Flight Hit By Severe TurbulenceCiti Trader Got 711 Warning Messages Before Sparking Flash Crash‘It Felt Like We Had Crashed’: Singapore Air Passenger Describes
- Zacks
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
- Zacks
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
